AIM ImmunoTech: Ownership Filing Amendment

Ticker: AIM · Form: SC 13D/A · Filed: Jul 30, 2024 · CIK: 946644

Aim Immunotech INC. SC 13D/A Filing Summary
FieldDetail
CompanyAim Immunotech INC. (AIM)
Form TypeSC 13D/A
Filed DateJul 30, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: ownership-change, sec-filing, schedule-13d

Related Tickers: AIM

TL;DR

Kellner & Deutsch filed a 13D amendment for AIM ImmunoTech - ownership change incoming.

AI Summary

On July 26, 2024, Todd Deutsch and Ted D. Kellner filed an amendment (Amendment No. 5) to their Schedule 13D for AIM ImmunoTech Inc. The filing indicates a change in the beneficial ownership of the company's common stock. The specific details of the change in ownership percentage or the exact number of shares acquired or disposed of are not explicitly stated in this excerpt, but the filing is a required disclosure for significant beneficial owners.

Why It Matters

This filing signals a potential shift in control or influence over AIM ImmunoTech Inc. by major shareholders, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or indicate activist investor involvement, which can introduce volatility.

Key Players & Entities

FAQ

What is the specific nature of the change in beneficial ownership reported in this amendment?

This excerpt does not specify the exact nature or extent of the change in beneficial ownership, only that an amendment to the Schedule 13D has been filed.

Who are the primary individuals filing this Schedule 13D amendment?

The primary individuals filing are Todd Deutsch and Ted D. Kellner.

What is the CUSIP number for AIM ImmunoTech Inc. common stock?

The CUSIP number for AIM ImmunoTech Inc. common stock is 00901B105.

When was the event that required this filing to be made?

The date of the event which requires the filing of this statement is July 26, 2024.

What was AIM ImmunoTech Inc. formerly known as?

AIM ImmunoTech Inc. was formerly known as HEMISPHERX BIOPHARMA INC.

Filing Stats: 994 words · 4 min read · ~3 pages · Grade level 7.8 · Accepted 2024-07-30 07:14:55

Key Financial Figures

Filing Documents

is hereby supplemented as follows

Item 4 is hereby supplemented as follows: On July 26, 2024, Mr. Kellner filed a motion for reargument with the Delaware Supreme Court. Mr. Kellner requested that the court declare he is entitled to relief from the inequitable conduct of the AIM board of directors and that the action be remanded for further proceedings requiring AIM to accept Mr. Kellners nominations at the next annual or special meeting. The motion also asked for clarification that the trial court retains jurisdiction for any fee applications. Mr. Kellners motion was denied on July 29, 2024. The Reporting Persons continue to review alternatives that may be available to them as described in Amendment No. 4. In connection with this review, the Reporting Persons note that the Company has announced that it plans to amend its bylaws to comport with the ruling of the Delaware Supreme Court. The Reporting Persons will consider the Companys amended bylaws once available. Item6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

is hereby supplemented as follows

Item 6 is hereby supplemented as follows: The Group Agreement entered into by the Reporting Persons and Mr. Chioini on July 26, 2023, as amended on January 3, 2024, automatically expired in accordance with its terms on July 26, 2024. Notwithstanding the expiration of the Group Agreement, the Reporting Persons, together with Mr. Chioini, continue to coordinate with respect to the actions described in Item 4 above. As such, the Reporting Persons would likely be deemed to remain a group within the meaning of Section 13(d) of the Exchange Act. The Reporting Persons, together with Mr. Chioini, expect to consider whether to renew or replace the Group Agreement as part of their ongoing review.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct. Date: July 30, 2024 TODD DEUTSCH By: /s/ Todd Deutsch TED D. KELLNER By: /s/ Ted D. Kellner

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on Read The Filing